Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Riliprubart by Sanofi for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...
Riliprubart by Sanofi for Polyradiculoneuropathy: Likelihood of Approval
Riliprubart is under clinical development by Sanofi and currently in Phase I for Polyradiculoneuropathy. According to GlobalData, Phase I drugs...
Riliprubart by Sanofi for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Riliprubart is under clinical development by Sanofi and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData,...